Loading…
Propanc Biopharma, Inc. is projected to decline to $1.02 by 2027, a -3% move from its current price of $1.05. PPCB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.9575 | $1.05 | $1.15 | +0.04% |
| Aug 6 | $0.9219 | $1.05 | $1.20 | +0.08% |
| Aug 7 | $0.8955 | $1.05 | $1.23 | +0.13% |
| Aug 8 | $0.874 | $1.05 | $1.27 | +0.17% |
| Aug 9 | $0.8554 | $1.05 | $1.29 | +0.21% |
| Aug 10 | $0.839 | $1.05 | $1.32 | +0.25% |
| Aug 11 | $0.8243 | $1.05 | $1.35 | +0.30% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8243 | $1.05 | $1.35 | +0.30% |
| Week 2 | $0.7469 | $1.06 | $1.49 | +0.59% |
| Week 3 | $0.693 | $1.06 | $1.62 | +0.89% |
| Week 4 | $0.6509 | $1.06 | $1.73 | +1.19% |
| Week 5 | $0.6161 | $1.07 | $1.84 | +1.49% |
| Week 6 | $0.5865 | $1.07 | $1.95 | +1.79% |
| Week 7 | $0.5606 | $1.07 | $2.05 | +2.09% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Propanc Biopharma, Inc. is a development-stage biopharmaceutical healthcare company incorporated in 2007 and based in Camberwell, Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.
The company has research and collaboration agreements with the University of Jaén to undertake research activities for the POP1 Program and with the University of Granada to develop a synthetic recombinant version of PRP. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017.
Propanc Biopharma operates in the healthcare category and focuses on developing cancer therapies in Australia. The description notes its origin, name change, and collaborative research relationships that support its product development efforts. These details frame the asset as a early-stage biopharma company with ongoing academic partnerships.
Propanc Biopharma, Inc. trades under the symbol PPCB and is currently priced at $0.99 per share with a market capitalization of $2.26M. It is ranked 5425 by market cap.
The stock trades within a 30-day range of $0.5375 to $1.82, reflecting a narrow near-term trading band around the current level.
The forecasted path shows a path of gradual upside in the long run, with 2026 projected average near $0.99 and 2028 projected average near $1.32, and a long-run average of $4.25 with a max of $9.77 by 2050. The early years include flat or modest expectations (2026 avg $0.99; 2027 avg $0.9471) before a shift to higher levels in later years (e.g., 2028–2050).
A major floor 61.6% below — a decisive break under it would weaken the trend.
The nearest floor, 5.7% below — buyers have tended to step in here.
The nearest ceiling, 79.0% above — a clean break opens room to run.
A major ceiling 200.0% above — clearing it would confirm fresh momentum.
Key PPCB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PPCB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.11 | Sell | $1.11 | Sell |
| MA 10 | $1.26 | Sell | $1.23 | Sell |
| MA 20 | $1.47 | Sell | $1.38 | Sell |
| MA 50 | $1.59 | Sell | $1.76 | Sell |
| MA 100 | $2.14 | Sell | $4.59 | Sell |
| MA 200 | $9.42 | Sell | $16.80 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 29.78 | Buy |
| Stoch RSI (14) | 11.45 | Buy |
| CCI (20) | -144.97 | Sell |
| Williams %R (14) | -96.88 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | -38.04 | Sell |
| Bollinger %B (20,2) | 0.06 | Neutral |
| Stochastic %K (14) | 3.12 | Buy |
| TRIX (15) | -0.98 | Sell |
| Awesome (5,34) | -0.43 | Sell |
| Ultimate (7,14,28) | 16.47 | Buy |
| Momentum (10) | -0.48 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 0.95 | Buy |
| ADX (14) | 22.33 | Sell |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is NEUTRAL with RSI14 at 30. This places momentum near the lower end of the typical neutral zone.
Near-term price action sits around a support level of $0.99 and faces resistance at $1.93, with the 30-day range spanning $0.5375 to $1.82. The SMA50 is $1.63, while the SMA200 stands at $9.86, highlighting a wide long-term moving-average backdrop relative to the near-term price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.99 | $1.05 | $1.49 | 0% | Neutral | |
| $0.7433 | $1.02 | $1.51 | -3% | Neutral | |
| $0.9441 | $1.38 | $2.18 | +31% | Bullish | |
| $1.08 | $1.67 | $2.77 | +59% | Bullish | |
| $1.05 | $1.70 | $2.94 | +62% | Bullish | |
| $0.914 | $1.54 | $2.76 | +47% | Bullish | |
| $0.8371 | $1.47 | $2.72 | +40% | Bullish | |
| $0.8246 | $1.51 | $2.87 | +44% | Bullish | |
| $0.668 | $1.27 | $2.48 | +21% | Bullish | |
| $0.8435 | $1.67 | $3.33 | +59% | Bullish | |
| $0.7717 | $1.71 | $3.76 | +63% | Bullish | |
| $2.02 | $4.49 | $10.32 | +327% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.99 | $1.05 | $1.38 | +0.00% |
| September 2026 | $0.9654 | $1.17 | $1.49 | +11.76% |
| October 2026 | $0.8853 | $1.09 | $1.41 | -7.02% |
| November 2026 | $0.8447 | $1.05 | $1.38 | -3.49% |
| December 2026 | $0.8882 | $1.12 | $1.49 | +6.26% |
Click any year to see its month-by-month PPCB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, PPCB is projected to trade between $0.99 and $1.49, averaging $1.05 — a potential gain of 0% from today's $1.05. Price action looks broadly range-bound.
Propanc Biopharma, Inc.'s 2027 outlook centres on $1.02, within a $0.7433 to $1.51 range. That is -3% versus the projected 2026 average. That marks a -3% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, PPCB could reach as high as $2.18, with a base case around $1.38 and support toward $0.9441 — roughly +31% from $1.05. Momentum favours further upside here.
Expect PPCB to range from $1.08 to $2.77 through 2029. The $1.67 average target implies a +59% move from current prices. That is up +21% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The PPCB price prediction for 2030 points to an average of $1.70 (low $1.05, high $2.94) — a potential gain of +62% on today's $1.05. Momentum favours further upside here.
In 2031, PPCB is projected to trade between $0.914 and $2.76, averaging $1.54 — a potential gain of +47% from today's $1.05. That is -9% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
Propanc Biopharma, Inc.'s 2032 outlook centres on $1.47, within a $0.8371 to $2.72 range. That is -4% versus the projected 2031 average. That marks a +40% change versus current levels. Momentum favours further upside here.
By 2033, PPCB could reach as high as $2.87, with a base case around $1.51 and support toward $0.8246 — roughly +44% from $1.05. Buyers look set to stay in control over this stretch.
Expect PPCB to range from $0.668 to $2.48 through 2034. The $1.27 average target implies a +21% move from current prices. That is -16% versus the projected 2033 average. Momentum favours further upside here.
The PPCB price prediction for 2035 points to an average of $1.67 (low $0.8435, high $3.33) — a potential gain of +59% on today's $1.05. Buyers look set to stay in control over this stretch.
In 2040, PPCB is projected to trade between $0.7717 and $3.76, averaging $1.71 — a potential gain of +63% from today's $1.05. That is up +3% on the projected 2035 average. Momentum favours further upside here.
Propanc Biopharma, Inc.'s 2050 outlook centres on $4.49, within a $2.02 to $10.32 range. That is up +162% on the projected 2040 average. That marks a +327% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in PPCB today (≈ 952.380952 PPCB) could be worth
$4,272.83
+$3,272.83 (+327%) by 2050 · US Dollar
Based on the average projected PPCB price of $4.49 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PPCBwould be worth at today's price.
$1,000 invested in PPCB on Jul 31, 2025 (≈ 4.004004 PPCB) would be worth
$4.2
-$995.8 (-99.6%) today · 0.00× · US Dollar
Based on a PPCB entry price of $249.75 vs. today's $1.05.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.37 | $766.42 | -23.4% |
| 1 month ago | $1.44 | $729.17 | -27.1% |
| 3 months ago | $2.58 | $406.58 | -59.3% |
| 6 months ago | $5.72 | $183.49 | -81.7% |
| 1 year ago | $249.75 | $4.2 | -99.6% |
| All time (5.0y) ago | $1,905 | $0.55 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PPCB forecast.
Our base-case forecast reaches $2.10 around 2050.
Implied market cap at $2.10: $4.78M
The multi-year forecast outlines a bullish trajectory beyond 2026, with 2028 averaging $1.32 and 2029 averaging $1.58, delivering ROIs of 33% and 60.1% respectively. For 2030 the average is $1.57 with a 59.1% ROI, and 2031–2033 show continued bullish momentum with average prices around $1.47–$1.40 and ROIs of 48.1% to 41.4%.
By 2034 the average falls to $1.21 with a 22.3% ROI, then strengthens again in 2035 to an average of $1.59 and a max of $3.17, for a 60.7% ROI. The forecast remains bullish into 2040 with an average of $1.64 and a max of $3.59 (65.4% ROI).
The long-term horizon culminates in 2050 with a min of $1.91, an average of $4.25, and a max of $9.77, delivering a 329.3% ROI. Overall, the outlook shows rising price potential in later years along with meaningful upside in certain years, but also periods of lower or flat returns. These figures are estimates and not guarantees.
Tap a question to reveal the answer.
For 2030, the forecast shows a min of $0.9758, an average of $1.57 and a max of $2.73, with a 59.1% ROI and a bullish sentiment.
The forecast presents a path of bullish momentum in later years, with positives such as 2028 (avg $1.32, ROI 33%), 2029 (avg $1.58, ROI 60.1%), 2030 (avg $1.57, ROI 59.1%), and a strong 2050 (avg $4.25, ROI 329.3%). However, it also includes a near-term negative in 2027 (ROI -4.3%). These are estimates and do not guarantee performance.
Yes, the forecast shows a 2035 max of $3.17, with an average of $1.59, indicating the potential to exceed $3 in the nearer mid-term if the top-end outcome occurs.
The current price is $0.99 and the market capitalization is $2.26M.
The 30-day range is $0.5375 to $1.82 and the annualized volatility is 200%.
Propanc Biopharma, Inc. Community Discussion
0Share your Propanc Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.